Fulcrum Therapeutics EBITDA 2018-2025 | FULC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Fulcrum Therapeutics ebitda from 2018 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Fulcrum Therapeutics ebitda from 2018 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$213.3B
Amgen (AMGN)	$158.5B
Gilead Sciences (GILD)	$134.6B
Vertex Pharmaceuticals (VRTX)	$118.1B
Bristol Myers Squibb (BMY)	$96.4B
CSL (CSLLY)	$81.2B
GSK (GSK)	$74.3B
Regeneron Pharmaceuticals (REGN)	$58.6B
Alnylam Pharmaceuticals (ALNY)	$41.8B
Argenex SE (ARGX)	$34.6B
BioNTech SE (BNTX)	$26.4B
Royalty Pharma (RPRX)	$20B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.3B
Illumina (ILMN)	$15.2B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.1B
Exelixis (EXEL)	$12.1B
Moderna (MRNA)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.4B
Exact Sciences (EXAS)	$9.5B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.2B
Roivant Sciences (ROIV)	$7.8B
Legend Biotech (LEGN)	$7.6B